Načítá se...
EZH2 targeting in medulloblastoma reduces tumor growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway
Medulloblastoma is a malignant pediatric tumor for which new therapies are urgently needed. We demonstrate that treatment with EPZ-6438 (Tazemetostat), an enhancer of zeste homologue 2 (EZH2) inhibitor approved for clinical trials, blocks MB cell growth in vitro and in vivo, and prolongs survival in...
Uloženo v:
| Vydáno v: | Oncogene |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780546/ https://ncbi.nlm.nih.gov/pubmed/31582835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-019-1036-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|